Skip to content

Impact of systemic manifestations/comorbidities on clinical state, prognosis and utilisation of health care resources in patients with COPD

Impact of systemic manifestations/comorbidities on clinical state, prognosis and utilisation of health care resources in patients with COPD - COSYCONET-Kohorte

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00000284
Enrollment
3500
Registered
2010-04-21
Start date
2010-09-16
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

J44.8 J44.9

Interventions

Group 1: In the COSYCONET Study the correlation between pulmonary disorders, comorbidities and systemic inflammation in patients with COPD would be observed in a cross sectional and longitudinal way.

Sponsors

Philipps-Universität Marburg
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis COPD (GOLD criteria) or chronic cough written informed consent cognitive and physical ability to meet the demands of the study protocol Available for repeated study visits over 18 months

Exclusion criteria

Exclusion criteria: Having undergone lung surgery (e.g. lung volumen reduction, lung transplant) Patients with lung cancer under treatment Moderate or severe exacerbation within the last 4 weeks Unable to walk or to understand the intention of the project

Design outcomes

Primary

MeasureTime frame
Main outcome will be the multidimensional BODE-Score: based on the Body-Mass-Index, FEV1, Dyspnoe (modified MRC-Scale),and the physical capacity (measured ny 6-minute-walk-test). The Bode-Score will be assessed at baseline, 6, 18, 36, 572, 90and 108 months after first visit in the study centres. Progression is defined as a change in BODE-Score by >=1 point over the observation period

Secondary

MeasureTime frame
Number of hospitalization during the observation period: patients will be ask how often they were hospitalised in the last year (at baseline) or since the last visit (after 6, 18, 36, 54, 72, 90 and 108 months). All cause mortality rate: assessed by the study centres 6, 18, 36, 54, 72, 90 and 108 months after inlcusion. || Comorbidities: will be asked by the studycentres based on a list of diseases. The following examinations will be performed at each visite: Nutritional status: Bioimpedance, waist circumstance Labaratory tests: Lipid status, Haemoglobin, haematocrit, glucose, Markers of systemic inflammation and aging: IL-6, IL-8, TNF-alpha, firinogen, NT-NT-pro BNP, telomere lenght Cardiovascular diseases: ECG at rest, Echocardiographie at rest, Ankle-Arm-Index, Carotid artery intima-media thickness Quality of life: EQ-5D (Questionnaire) Depression: PHQ-D (Questionnaire) Cognitive impairement: (DemTec) physical activity: IPAQ (Questionnaire)

Countries

Germany

Contacts

Public ContactSandra Söhler

Philipps-Universität Marburg Klinik für Innere Medizin mit Schwerpunkt Pneumologie Geschäftsstelle Kompetenznetz Asthma/COPD

sandra.soehler@staff.uni-marburg.de06421-586 4536

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 14, 2026